ACCESS

EU-JAMRAI2 aims to provide substantial assistance to Member States (MS) in the development and periodic updating of their National Action Plans (NAPs) on Antimicrobial Resistance (AMR). By offering direct and significant support, the initiative seeks to enhance the capacity of MS to effectively tackle AMR within their healthcare systems. Secondly, EU-JAMRAI2 endeavors to bolster the responsiveness and coordination of health systems across the Union, thereby safeguarding individuals from the threat of AMR. Through improved collaboration and streamlined efforts, the initiative aims to fortify the resilience of healthcare systems against the proliferation of drug-resistant infections.

One of the main objectives of EU-JAMRAI2 in this field is to improve access to selected AMR-related products both for human and veterinarian use:

High-priority products

EU-JAMRAI2 is working to identify products with vulnerable supply per country to drive its actions on evidence-based reports.

Click on each country on the map to find out about the high-priority products.

France

Content is not available

Spain

Phenoximethylpenicillin benzatine (Human)
Cefadroxil (Human)
Aztreonam (Human)
Amikacin (Human)
Trimetoprim and Sulfamethoxazole (Human)
Oxytetracycline (Veterinary)

Download a full list

*This list is not complete and more products will be added soon.

Belgium

Content is not available

Bulgaria

Eravacycline (human)
Benzylpenicillin (human)
Phenoxymethylpenicillin (human)
Ceftaroline (human pediatric only)
Erythromycin (human)
Tobramycin (human)
Nitrofurantoin (human)
Fosfomycin (human)
Daptomycin (human)
Amphotericin B “liposomal” (human)

Download a full list

Denmark

Ampicillin (human and veterinay)
Pivmecillinam (human)
Benzylpenicillin (/procaine benzylpenicillin) (human and veterinary)
Phenoxymethylpenicillin (human and veterinary)
Flucloxacillin (human, pediatric)
Gentamicin (human and veterinary)
Nitrofurantoin (human)
Fosfomycin (human)
Rifampicin (human and veterinary)
Amoxicillin (veterinary)
Sulfadiazine, Trimethoprim (veterinary)
Fucidic acid (veterinary)

Download a full list

Finland

Content is not available

Iceland

Content is not available

Italy

Content is not available

Netherlands

Content is not available

Norway

Benzylpenicillin (human and veterinary)
Dicloxacillin (human)
Doxycycline (human)
Flucloxacillin (human pediatric only)
Gentamicin (human)
Phenoxymethylpenicillin (human)
Pivmecillinam (human)
Tuberculosis antibiotics (human)
Vaccines for salmon (veterinary)

Download a full list

Poland

Content is not available

Slovenia

Content is not available

Sweden

Amoxicillin (human)
Temocillin (human)
Phenoxymethylpenicillin (human)
Ceftibuten (human)
Trimethoprim, sulfamethoxazole (human)
Colistin (human)
Pivmecillinam (human)
Rifampicin (human)
Procaine benzylpenicillin (veterinary)
Trimethoprim, sulfadiazine (veterinary)

Download a full list

Malta

Amoxicillin (Human)
Temocillin (Human)
Cefalexin (Human)
Amikacin (Human)
Cefazolin (Human)
Aztreonam (Human)
Co-trimoxazole (Human)
Clindamycin (Human)
Fosfomycin (Human)

Download a full list

Targeted interventions

EU-JAMRAI2 identifies and supports the implementation of targeted interventions to improve selected narrow-spectrum alternatives or use relevant diagnostic tools, according to each national context.

Demand barriers

Through the collaboration of the participant countries, the Joint Action spots the demand barriers for these products, behavioral, financial or product-related

Supply barriers

In collaboration with EMA and other national medicine authorities, the participants in the Joint Action analyses supply-side barriers and interventions related to selected antibiotics and diagnostics.

New Products

Through extensive discussion forums, EU-JAMRAI2 evaluates the incentives for innovation and the potential implementation of a framework for alternative methods to antibiotics.